Public research overviewHow we research Research team
Companion animal health market context
Companion animal health brings together preventive products, treatments, diagnostics and veterinary services for animals kept as companions. Zoetis's portfolio illustrates the breadth: it includes parasiticides, vaccines, dermatology and pain products, and diagnostics, with offerings for dogs, cats and horses. Veterinarians select and deliver care, while owners weigh the need for care against its cost; suppliers must therefore serve both professional and owner-facing needs.
Commercial models differ by product and jurisdiction. Elanco describes US pet-health sales through veterinary and retail channels, including prescription and over-the-counter products. An authorized product, a listed product and a product that is actually available to a particular buyer are distinct commercial statuses.
Sources and supporting claims 3
- Zoetis at a Glance (opens in a new tab)zoetis.com
- Zoetis identifies parasiticides, vaccines, dermatology, pain and animal health diagnostics among its major product categories and serves dogs, cats and horses.
- Talking with clients: Discussing the cost of care (opens in a new tab)axon.avma.org
- AVMA describes US research indicating that pet owners want more proactive conversations about veterinary care costs.
- Broad, Omnichannel Portfolio Driving Scale and Customer Reach (opens in a new tab)investor.elanco.com
- Elanco reports US pet-health sales through both veterinary and retail channels, including prescription and over-the-counter portfolios.
360iResearch introduction
Inside the research
Coverage at a glance
Selected branches from the published table of contents. Follow a chapter to see every subchapter in context.
Chapter 8 Offering Type
- Segment Overview
- Medicinal Products
- Diagnostic Products
- Diagnostic Services
Chapter 9 Diagnostic Platform
- Segment Overview
- Immunoassays
- Genetic Analysis
Chapter 10 Health Application
- Segment Overview
- Parasite Prevention & Control
- Preventive Care & Health Assessment
- Infectious Disease Prevention & Management
Companion animal health: launches and channel shifts
Commercial competition is moving on two fronts. Elanco reported adding Costco and Dollar General as US parasiticide retail customers in early 2026, while also reporting Credelio Quattro launches in Australia, Canada and Japan by August 2026. The retail additions expand named routes to pet owners; the launches establish company-reported entry, not equivalent clinic coverage in each country.
Product life-cycle changes can also alter competition, but their status matters. On November 5, 2026, the European Medicines Agency's veterinary committee recommended a Credelio variation concerning an additional cat indication. That recommendation was not itself the European Commission's grant of the variation.
Sources and supporting claims 3
- Elanco Animal Health Reports First Quarter 2026 Results (opens in a new tab)investor.elanco.com
- Elanco said it added Costco and Dollar General as US retail customers for parasiticides by its first-quarter 2026 results.
- Elanco Animal Health Reports Second Quarter 2026 Results (opens in a new tab)investor.elanco.com
- In August 2026, Elanco reported that Credelio Quattro had launched in Australia, Canada and Japan.
- Credelio - opinion on variation to marketing authorisation (opens in a new tab)ema.europa.eu
- On November 5, 2026, the EMA committee adopted a positive opinion recommending a variation for Credelio concerning a cat indication; the opinion states that the variation requires a European Commission grant.
AI in companion animal practice commerce
Vetspire offers an AI Scribe that transcribes client conversations and suggests encounter notes for veterinary teams to review. Its documentation says access to encounter AI features depends on the organization's subscription and location settings. This is evidence of a commercial offering, not of market-wide adoption or measured productivity gains.
The business implication is conditional: if documentation tools reduce administrative burden without creating unacceptable review or privacy costs, practices may value them alongside existing software. Suppliers should assess subscription fit, staff review time, data handling and customer acceptance before expanding deployment. Public evidence inspected here does not establish how widely companion-animal practices use these tools or whether AI changes product purchasing.
Sources and supporting claims 2
- About AI Scribe (Web Version) (opens in a new tab)manual.vetspire.com
- Vetspire describes an AI Scribe offering that transcribes client conversations and suggests encounter notes for user review.
- Vetspire AI (opens in a new tab)manual.vetspire.com
- Vetspire states that encounter AI features are available only at locations enabled under an organization's subscription and location settings.
Regional companion animal health access
North America: Zoetis reported that higher US sales of Simparica Trio, dermatology products and small-animal diagnostics contributed to 2025 companion-animal growth, partly offset by lower Librela sales. This is one supplier's experience, not a regional market total. Latin America: Brazil's agriculture ministry provides registration information for veterinary products; market entry still requires product-specific commercial and distribution evidence.
Europe: EU veterinary medicines may be authorized nationally or EU-wide. That creates a common route for eligible products, but local availability remains a separate question. Middle East: Saudi veterinary guidance distinguishes prescription-only, over-the-counter and controlled supply categories, making product classification relevant to channel choice; the finding should not be extended to the entire region.
Africa: Zoetis South Africa lists dog and cat products including Revolution and Simparica. The listing indicates a local portfolio, not sales across Africa. Asia-Pacific: China registered a feline diagnostic kit in January 2026, while South Korea reported 2025 authorizations that included domestically developed dog heart-disease medicines. These are distinct national regulatory events, not evidence of region-wide adoption.
Sources and supporting claims 7
- Zoetis 2025 Annual Report (opens in a new tab)zoetis.com
- Zoetis reported that 2025 US companion-animal growth included increased sales of Simparica Trio, dermatology products and small-animal diagnostics, partly offset by lower Librela sales.
- Produtos Veterinários (opens in a new tab)gov.br
- Brazil's agriculture ministry provides registration guidance and information about registered veterinary pharmaceutical and biological products.
- Veterinary medicines (opens in a new tab)food.ec.europa.eu
- EU veterinary medicines can be authorized nationally or through an EU-wide procedure, and Regulation 2019/6 provides harmonized rules.
- Classifying Legal Status of Veterinary Medicinal Products Guidance (opens in a new tab)sfda.gov.sa
- Saudi guidance distinguishes prescription-only, over-the-counter and controlled categories of veterinary medicines.
- Products (opens in a new tab)zoetis.co.za
- Zoetis South Africa lists companion-animal products for cats and dogs, including Revolution and Simparica.
- 农业农村部公告 第981号(批准21种兽药产品注册、8种兽药产品变更注册、2种兽药产品转国内生产) (opens in a new tab)xmsyj.moa.gov.cn
- China's January 2026 announcement approved registration of a feline diagnostic kit among other veterinary products.
- 검역본부, ‘동물용 신약 전담 심사팀’으로 업계 맞춤형 지원 이어나가 (opens in a new tab)mafra.go.kr
- South Korea's agriculture ministry reported that domestically developed dog heart-disease medicines were among veterinary new drugs authorized in 2025.
Companion animal access across geographic groupings
ASEAN: Its 2017 animal-vaccine registration mechanism describes regional coordination with national-authority involvement. Singapore's current requirements also provide a country-specific example of vaccine registration and licensing. The review did not establish how the regional mechanism is implemented across every ASEAN market.
BRICS: Brazil's registration information and China's product-specific registration illustrate separate national evidence; they do not establish a common BRICS authorization or a shared sales channel. European Union: An EU-wide veterinary-medicine authorization route exists alongside national routes, but neither route alone demonstrates that a product is on sale in every member state.
G7: The US channel evidence and Great Britain's national Zenrelia authorization show why portfolio and access planning must remain jurisdiction-specific; they do not characterize every G7 market. GCC: Saudi Arabia's distinction between prescription and over-the-counter veterinary products is relevant to channel selection there, but should not be assumed to apply identically across the GCC. NATO: This review found no companion-animal commercial-access record sufficient to support a NATO-wide market conclusion; national product and channel evidence is needed instead.
Sources and supporting claims 5
- Veterinary medicines (opens in a new tab)food.ec.europa.eu
- The European Commission describes national and EU-wide veterinary-medicine authorization routes.
- Classifying Legal Status of Veterinary Medicinal Products Guidance (opens in a new tab)sfda.gov.sa
- Saudi Arabia's veterinary-medicine guidance distinguishes prescription-only and over-the-counter supply categories.
- Importing veterinary vaccines (opens in a new tab)avs.nparks.gov.sg
- Singapore requires veterinary vaccines to be evaluated and registered before import and requires licensing for import.
- Mechanism for the ASEAN Registration of Animal Vaccine (opens in a new tab)asean.org
- ASEAN's animal-vaccine registration mechanism was adopted in 2017 and describes national-authority involvement.
- Product Information Database: Zenrelia 15 mg Film-coated Tablets for Dogs (opens in a new tab)vmd.defra.gov.uk
- Great Britain's veterinary product database lists Zenrelia for dogs as nationally authorized from July 7, 2025, with veterinary-prescription distribution.
Featured companion animal health countries
Australia, Canada and Japan: Elanco reported Credelio Quattro launches in all three by August 2026. The disclosure does not establish comparable local clinic coverage or sales. Brazil: The agriculture ministry provides veterinary-product registration information; product-level registration and channel access remain separate questions. China: The January 2026 feline diagnostic registration is a specific access milestone, not evidence of current sales.
France, Germany, Italy and Spain: Each falls within the EU veterinary-medicine framework, including the possibility of EU-wide authorization. Availability still needs to be established product by product and country by country. India: The national authorization list records Biovet's dog rabies vaccine authorization in 2023; the record does not establish current distribution. Mexico: Zoetis's local dog portfolio lists Simparica and Simparica Trio, but the listing does not establish sales or market share.
Russia: MSD Animal Health's Russian pet portfolio page lists vaccines and antiparasitic categories; current supply and transaction volumes were not established. South Korea: The 2025 authorizations included domestically developed dog heart-disease medicines, but authorization is not proof of commercial uptake. United Kingdom: Great Britain's database records a national Zenrelia authorization for dogs from July 2025; that record is specific to Great Britain. United States: Zoetis reported different 2025 sales movements across companion-animal categories, underscoring the need to assess each product rather than extrapolate from one launch.
Sources and supporting claims 11
- Elanco Animal Health Reports Second Quarter 2026 Results (opens in a new tab)investor.elanco.com
- Elanco reported launches of Credelio Quattro in Australia, Canada and Japan by August 2026.
- Zoetis 2025 Annual Report (opens in a new tab)zoetis.com
- Zoetis reported differing 2025 US sales movements across companion-animal product categories.
- Produtos Veterinários (opens in a new tab)gov.br
- Brazil's agriculture ministry provides information on veterinary product registration and registered products.
- Veterinary medicines (opens in a new tab)food.ec.europa.eu
- France, Germany, Italy and Spain fall within the EU framework under which veterinary medicines can be authorized nationally or EU-wide.
- 农业农村部公告 第981号(批准21种兽药产品注册、8种兽药产品变更注册、2种兽药产品转国内生产) (opens in a new tab)xmsyj.moa.gov.cn
- China's agriculture ministry announced registration of a feline diagnostic kit in January 2026.
- 검역본부, ‘동물용 신약 전담 심사팀’으로 업계 맞춤형 지원 이어나가 (opens in a new tab)mafra.go.kr
- South Korea reported authorizations in 2025 that included domestically developed dog heart-disease medicines.
- Product Information Database: Zenrelia 15 mg Film-coated Tablets for Dogs (opens in a new tab)vmd.defra.gov.uk
- Great Britain's product database lists a national authorization for Zenrelia for dogs from July 7, 2025.
- Approval for Import & Marketing Authorization (Form -45 & 46) Approved in 2023/2024 (opens in a new tab)cdsco.gov.in
- India's CDSCO list records a 2023 authorization for Biovet's veterinary rabies vaccine for dogs.
- Perros (opens in a new tab)zoetis.mx
- Zoetis's Mexico dog portfolio lists Simparica and Simparica Trio.
- МДЖ - MSD Animal Health Russia (opens in a new tab)msd-animal-health.ru
- MSD Animal Health's Russian pet page lists vaccines and antiparasitic categories for companion animals.
- Union Product Database (opens in a new tab)ema.europa.eu
- The EMA says its veterinary medicines information website can identify the Member States in which a particular authorized medicine is available.
Commercial choices for companion animal health leaders
Choose channels by product and jurisdiction. Where a product can be sold through retail, compare the reach of retail partners with the relationships and service support available through veterinary clinics. Elanco's US mix shows both routes are commercially relevant, but it does not establish the economics for another supplier. Favor clinic-led coverage when the product's legal status or buyer-support needs make a retail route unsuitable.
Stage geographic investment. Use authorization and launch records as entry milestones, then look for product-specific availability and repeat demand before committing to broad promotion. EU authorization can support a coordinated strategy, but country availability remains a separate question. A local partnership may be preferable to a direct launch where distribution coverage or counterparty responsibilities are uncertain.
Make the buyer proposition explicit. Assess whether clinics can explain both the offering and its cost to owners. If affordability or service capacity constrains uptake, a narrower portfolio and stronger customer support may be preferable to adding more products. Revisit that choice when observed orders, retention and channel economics justify expansion.
Sources and supporting claims 5
- Talking with clients: Discussing the cost of care (opens in a new tab)axon.avma.org
- AVMA's US client-communication material identifies cost discussions as a relevant buyer concern.
- Broad, Omnichannel Portfolio Driving Scale and Customer Reach (opens in a new tab)investor.elanco.com
- Elanco's 2025 US pet-health channel mix included both retail and veterinary channels.
- Elanco Animal Health Reports Second Quarter 2026 Results (opens in a new tab)investor.elanco.com
- Elanco reported geographic launches of Credelio Quattro and US veterinary-clinic uptake in its second-quarter 2026 results.
- Veterinary medicines (opens in a new tab)food.ec.europa.eu
- The EU has both national and EU-wide veterinary-medicine authorization routes.
- Union Product Database (opens in a new tab)ema.europa.eu
- The EMA's product information database distinguishes authorized medicines from information about their availability in individual Member States.
Companion animal health research method
This qualitative review inspected company portfolios and disclosures, veterinary software documentation, and public regulatory records available through November 9, 2026. It compared stated launches, product listings, authorizations and proposed regulatory changes without treating them as equivalent evidence of sales or availability. Native-language official material was inspected for Brazil, China and South Korea.
Coverage is selective rather than a census of providers or countries. Company statements describe their own businesses and may not independently establish market-wide patterns. Group-wide implementation, current local sales, pricing, distribution depth and AI adoption remain incompletely documented. No interviews, surveys, market sizing or experimental research were performed for this report.
Companion animal health outlook
The evidence points to competition across product categories, veterinary relationships and retail access rather than a single uniform global market. Elanco's reported geographic launches and Zoetis's differing US product sales movements illustrate both opportunity and variability.
Useful public milestones to watch include country-specific availability following launches, changes in authorized product indications and repeat channel uptake. In particular, the November 2026 Credelio committee recommendation should be distinguished from any later Commission decision. Commercial success, local supply and the economic impact of veterinary AI remain open questions.
Sources and supporting claims 3
- Elanco Animal Health Reports Second Quarter 2026 Results (opens in a new tab)investor.elanco.com
- Elanco reported Credelio Quattro launches in Australia, Canada and Japan and US clinic uptake.
- Credelio - opinion on variation to marketing authorisation (opens in a new tab)ema.europa.eu
- The European veterinary medicines committee recommended a Credelio variation for a cat indication on November 5, 2026.
- Zoetis 2025 Annual Report (opens in a new tab)zoetis.com
- Zoetis reported differing US companion-animal product sales movements in 2025.
Research report
Table of contents
- 1.About This Report
- 1.1Objectives of the Study
- 1.2Market Definition
- 1.3Scope & Coverage Summary
- 1.4Years Considered
- 1.5Currency Considered
- 1.6Language Considered for the Study
- 1.7Key Stakeholders
- 2.Decision Brief
- 2.1Headline Numbers
- 2.2Key Findings
- 2.3Where to Play
- 2.4Risks
- 3.Executive Summary
- 3.1Market Size & Growth Snapshot
- 3.2Strategic Implications for Leaders
- 3.3Top Revenue Opportunities
- 3.4Emerging Business Models
- 3.5Industry Roadmap
- 4.Market Size & Forecast
- 4.1Market Size & Growth
- 4.2Growth Contribution by Segment, Region & Country
- 4.3Market Outlook
- 4.3.1Near-Term Market Outlook (0-2 Years)
- 4.3.2Medium-Term Market Outlook (3-5 Years)
- 4.3.3Long-Term Market Outlook (5-10 Years)
- 5.Market Dynamics
- 5.1Growth Drivers
- 5.1.1Established wholesale routes can enable professional purchasing
- 5.1.2Authorized alternatives can support channel-enabled substitution
- 5.2Restraints
- 5.2.1Product and professional authorization constrain immediate access
- 5.2.2Organized buyers can constrain supplier commercial terms
- 5.3Opportunities
- 5.3.1Making diagnostic commitments fit the practice
- 5.3.2Connecting lawful access with household fulfillment
- 5.3.3Defining accountability around therapeutic-device purchases
- 5.4Challenges
- 5.4.1Establishing current distributor access and commitments
- 5.4.2Coordinating retail promotion with supply-policy obligations
- 5.4.3Distinguishing a potential alternate from dependable replacement supply
- 5.5Impact of Artificial Intelligence
- 5.1Growth Drivers
- 6.Industry Structure
- 6.1Value Chain & Ecosystem
- 6.1.1Supply-Side Analysis
- 6.1.2Demand-Side Analysis
- 6.1.3Stakeholder Analysis
- 6.2Porter’s Five Forces
- 6.3PESTLE Analysis
- 6.4Go-to-Market Strategy
- 6.1Value Chain & Ecosystem
- 7.Strategic Insights
- 7.1Opportunity Mapping
- 7.2Pricing Trends
- 7.3Channel Analysis
- 7.4Customer Insights
- 7.5Customer Experience Benchmarking
- 7.6Regulation & Standards
- 7.7ESG & Sustainability
- 7.8Risk Scenarios
- 7.9ROI & Cost-Benefit
- 8.Companion Animal Health Market, by Offering Type
- 8.1Segment Overview
- 8.2Medicinal Products
- 8.2.1Pharmaceuticals
- 8.2.2Vaccines
- 8.3Diagnostic Products
- 8.3.1Diagnostic Reagents & Test Kits
- 8.3.2Diagnostic Instruments
- 8.4Diagnostic Services
- 8.5Behavioral Health Products
- 8.6Therapeutic Devices
- 9.Companion Animal Health Market, by Diagnostic Platform
- 9.1Segment Overview
- 9.2Immunoassays
- 9.3Genetic Analysis
- 10.Companion Animal Health Market, by Health Application
- 10.1Segment Overview
- 10.2Parasite Prevention & Control
- 10.3Preventive Care & Health Assessment
- 10.4Infectious Disease Prevention & Management
- 10.5Dermatologic & Ear Health
- 10.6Pain & Mobility Management
- 10.7Endocrine & Metabolic Health
- 10.8Perioperative & Emergency Care
- 10.9Gastrointestinal Health
- 10.10Cardiovascular & Respiratory Health
- 10.11Renal & Urinary Health
- 10.12Behavioral Health
- 10.13Oncology
- 10.14Oral & Dental Health
- 10.15Neurologic Health
- 10.16Ophthalmic Health
- 10.17Hematologic & Immune Health
- 10.18Reproductive Health
- 11.Companion Animal Health Market, by Buyer
- 11.1Segment Overview
- 11.2Pet-owning Households
- 11.3Veterinary Healthcare Providers
- 11.4Institutional Animal Owners & Caretakers
- 12.Companion Animal Health Market, by Administration Route
- 12.1Segment Overview
- 12.2Oral
- 12.3Injectable
- 12.4Cutaneous
- 12.5Otic
- 13.Companion Animal Health Market, by Sales Channel
- 13.1Segment Overview
- 13.2Veterinary Dispensing
- 13.3Supplier Direct Sales
- 13.4Wholesale Distribution
- 13.5Pharmacy Sales
- 13.6Retail Sales
- 14.Companion Animal Health Market, by Animal Species
- 14.1Segment Overview
- 14.2Dogs
- 14.3Cats
- 14.4Multispecies
- 14.5Horses
- 14.6Small Mammals
- 14.7Birds
- 15.Companion Animal Health Market, by Regulatory Access
- 15.1Segment Overview
- 15.2Prescription Required
- 15.3No Prescription Required
- 16.Companion Animal Health Market in Asia-Pacific
- 16.1Regional Overview
- 16.2China
- 16.3India
- 16.4Japan
- 16.5Australia
- 16.6South Korea
- 17.Companion Animal Health Market in North America
- 17.1Regional Overview
- 17.2United States
- 17.3Canada
- 17.4Mexico
- 18.Companion Animal Health Market in Latin America
- 18.1Regional Overview
- 18.2Brazil
- 19.Companion Animal Health Market in Europe
- 19.1Regional Overview
- 19.2United Kingdom
- 19.3Germany
- 19.4France
- 19.5Russia
- 19.6Italy
- 19.7Spain
- 20.Companion Animal Health Market in Middle East
- 20.1Regional Overview
- 21.Companion Animal Health Market in Africa
- 21.1Regional Overview
- 22.Competitive Landscape
- 22.1Market Share Analysis
- 22.2Market Concentration
- 22.3Competitive Benchmarking
- 22.4Product Portfolio Analysis
- 22.5Recent Developments & Impact
- 23.Company Profiles
- 23.1Zoetis
- 23.2Boehringer Ingelheim Animal Health
- 23.3Elanco
- 23.4IDEXX
- 23.5Ceva
- 23.6Dechra
- 23.7Companion Animal Health
- 23.8Pets Drug Mart
- 23.9Midwest Veterinary Supply
- 23.10DPYP-VET
- 23.11SODISAV
- 23.12Intas Animal Health
- 24.Research Methodology
- 24.1Introduction
- 24.2Research Design
- 24.2.1Primary Research
- 24.2.2Secondary Research
- 24.3Research Framework
- 24.3.1Qualitative Analysis
- 24.3.2Quantitative Analysis
- 24.4Market Size Estimation
- 24.4.1Top-Down Approach
- 24.4.2Bottom-Up Approach
- 24.5Data Triangulation
- 24.6Research Outcomes
- 24.7Research Assumptions
- 24.8Research Limitations
- 25.Segmentation Coverage
- 26.Expert Panel
- 27.Companies Covered
- 28.Economic Groupings
- 28.1ASEAN
- 28.2GCC
- 28.3European Union
- 28.4BRICS
- 28.5G7
- 28.6NATO